We are analyzing https://link.springer.com/article/10.1007/s00262-003-0493-5.

Title:
Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study | Cancer Immunology, Immunotherapy
Description:
Peptides derived from over-expressed p53 protein are presented by class I MHC molecules and may act as tumour-associated epitopes. Due to the diversity of p53 mutations, immunogenic peptides representing wild-type sequences are preferable as a basis for a broad-spectrum p53-targeting cancer vaccine. Our preclinical studies have shown that wild-type p53-derived HLA-A2–binding peptides are able to activate human T cells and that the generated effector T cells are cytotoxic to human HLA-A2+, p53+ tumour cells. In this phase I pilot study, the toxicity and efficacy of autologous dendritic cells (DCs) loaded with a cocktail of three wild-type and three modified p53 peptides are being analysed in six HLA-A2+ patients with progressive advanced breast cancer. Vaccinations were well tolerated and no toxicity was observed. Disease stabilisation was seen in two of six patients, one patient had a transient regression of a single lymph node and one had a mixed response. ELISpot analyses showed that the p53-peptide–loaded DCs were able to induce specific T-cell responses against modified and unmodified p53 peptides in three patients, including two of the patients with a possible clinical benefit from the treatment. In conclusion, the strategy for p53-DC vaccination seems safe and without toxicity. Furthermore, indications of both immunologic and clinical effect were found in heavily pretreated patients with advanced breast cancer. An independent clinical effect of repeated administration of DCs and IL-2 can not of course be excluded; further studies are necessary to answer these questions.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cancer, google, scholar, pubmed, cas, cells, article, dendritic, patients, clinical, breast, wildtype, cell, immunol, immunotherapy, human, cytotoxic, peptide, claesson, peptides, vaccine, access, res, melanoma, svane, hlaa, natl, privacy, cookies, content, research, vaccination, advanced, pedersen, response, specific, responses, acad, sci, usa, jager, van, tumor, publish, search, phase, study, inge, marie, johnsen,

Topics {✒️}

p53-derived hla-a2-binding peptides wild-type p53-derived peptide wild-type p53-specific cd4 p53-peptide–pulsed dendritic cells wild-type p53-specific cytotoxic mage-3a1 peptide-pulsed mature month download article/chapter p53-peptide–loaded dcs high steady-state levels hla-a24 induces cytotoxic p53 tumor-suppressor gene c-erbb-2 oncoproteins overexpression cancer vaccination therapy human hla-a2+ cytotoxic t-lymphocyte clones primary ny-eso-1 immunity p53+ tumour cells full article pdf autologous dendritic cells human tumour immunology related subjects article cancer immunology unmodified p53 peptides hla-a2+ patients advanced breast cancer inge marie svane modified p53 peptides dendritic cells transduced stable dendritic cells melanoma patient vaccinated cancers overexpressing p53 targeting p53 general tumor antigen p53-dc vaccination wild-type peptide-vaccinated patients privacy choices/manage cookies national cancer institute expressed p53 protein t-helper cells danish cancer society increased ctl immunogenicity 1-restricted cytotoxic semin cancer biol ny-eso-1+ cancers check access instant access breast cancer article svane human ctl

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
         description:Peptides derived from over-expressed p53 protein are presented by class I MHC molecules and may act as tumour-associated epitopes. Due to the diversity of p53 mutations, immunogenic peptides representing wild-type sequences are preferable as a basis for a broad-spectrum p53-targeting cancer vaccine. Our preclinical studies have shown that wild-type p53-derived HLA-A2–binding peptides are able to activate human T cells and that the generated effector T cells are cytotoxic to human HLA-A2+, p53+ tumour cells. In this phase I pilot study, the toxicity and efficacy of autologous dendritic cells (DCs) loaded with a cocktail of three wild-type and three modified p53 peptides are being analysed in six HLA-A2+ patients with progressive advanced breast cancer. Vaccinations were well tolerated and no toxicity was observed. Disease stabilisation was seen in two of six patients, one patient had a transient regression of a single lymph node and one had a mixed response. ELISpot analyses showed that the p53-peptide–loaded DCs were able to induce specific T-cell responses against modified and unmodified p53 peptides in three patients, including two of the patients with a possible clinical benefit from the treatment. In conclusion, the strategy for p53-DC vaccination seems safe and without toxicity. Furthermore, indications of both immunologic and clinical effect were found in heavily pretreated patients with advanced breast cancer. An independent clinical effect of repeated administration of DCs and IL-2 can not of course be excluded; further studies are necessary to answer these questions.
         datePublished:2004-02-25T00:00:00Z
         dateModified:2004-02-25T00:00:00Z
         pageStart:633
         pageEnd:641
         sameAs:https://doi.org/10.1007/s00262-003-0493-5
         keywords:
            Dendritic cells
            Breast cancer
            Vaccine
            p53 peptides
            Immunotherapy
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb1.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5flb2.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb3.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb4.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb5.jpg
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:53
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Inge Marie Svane
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Anders E. Pedersen
               affiliation:
                     name:University of Copenhagen
                     address:
                        name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hans E. Johnsen
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dorte Nielsen
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Claus Kamby
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eva Gaarsdal
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kirsten Nikolajsen
               affiliation:
                     name:Herlev University Hospital
                     address:
                        name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Søren Buus
               affiliation:
                     name:University of Copenhagen
                     address:
                        name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mogens H. Claesson
               affiliation:
                     name:University of Copenhagen
                     address:
                        name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
      description:Peptides derived from over-expressed p53 protein are presented by class I MHC molecules and may act as tumour-associated epitopes. Due to the diversity of p53 mutations, immunogenic peptides representing wild-type sequences are preferable as a basis for a broad-spectrum p53-targeting cancer vaccine. Our preclinical studies have shown that wild-type p53-derived HLA-A2–binding peptides are able to activate human T cells and that the generated effector T cells are cytotoxic to human HLA-A2+, p53+ tumour cells. In this phase I pilot study, the toxicity and efficacy of autologous dendritic cells (DCs) loaded with a cocktail of three wild-type and three modified p53 peptides are being analysed in six HLA-A2+ patients with progressive advanced breast cancer. Vaccinations were well tolerated and no toxicity was observed. Disease stabilisation was seen in two of six patients, one patient had a transient regression of a single lymph node and one had a mixed response. ELISpot analyses showed that the p53-peptide–loaded DCs were able to induce specific T-cell responses against modified and unmodified p53 peptides in three patients, including two of the patients with a possible clinical benefit from the treatment. In conclusion, the strategy for p53-DC vaccination seems safe and without toxicity. Furthermore, indications of both immunologic and clinical effect were found in heavily pretreated patients with advanced breast cancer. An independent clinical effect of repeated administration of DCs and IL-2 can not of course be excluded; further studies are necessary to answer these questions.
      datePublished:2004-02-25T00:00:00Z
      dateModified:2004-02-25T00:00:00Z
      pageStart:633
      pageEnd:641
      sameAs:https://doi.org/10.1007/s00262-003-0493-5
      keywords:
         Dendritic cells
         Breast cancer
         Vaccine
         p53 peptides
         Immunotherapy
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb1.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5flb2.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb3.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb4.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-003-0493-5/MediaObjects/s00262-003-0493-5fhb5.jpg
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:53
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Inge Marie Svane
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Anders E. Pedersen
            affiliation:
                  name:University of Copenhagen
                  address:
                     name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hans E. Johnsen
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dorte Nielsen
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Claus Kamby
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eva Gaarsdal
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kirsten Nikolajsen
            affiliation:
                  name:Herlev University Hospital
                  address:
                     name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Søren Buus
            affiliation:
                  name:University of Copenhagen
                  address:
                     name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mogens H. Claesson
            affiliation:
                  name:University of Copenhagen
                  address:
                     name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:53
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Herlev University Hospital
      address:
         name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:Herlev University Hospital
      address:
         name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
         type:PostalAddress
      name:University of Copenhagen
      address:
         name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Inge Marie Svane
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Anders E. Pedersen
      affiliation:
            name:University of Copenhagen
            address:
               name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Hans E. Johnsen
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Dorte Nielsen
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Claus Kamby
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Eva Gaarsdal
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Kirsten Nikolajsen
      affiliation:
            name:Herlev University Hospital
            address:
               name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
               type:PostalAddress
            type:Organization
      name:Søren Buus
      affiliation:
            name:University of Copenhagen
            address:
               name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Mogens H. Claesson
      affiliation:
            name:University of Copenhagen
            address:
               name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
      name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
      name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
      name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
      name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
      name:Department of Oncology, Herlev University Hospital, Herlev, Denmark
      name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
      name:Department of Hematology, Herlev University Hospital, Herlev, Denmark
      name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
      name:Panum Institute, University of Copenhagen, Copenhagen, Denmark
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(123)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.72s.

LINK . SPRINGER . COM {}